Endometrial cancer

EJ Crosbie, SJ Kitson, JN McAlpine, A Mukhopadhyay… - The Lancet, 2022 - thelancet.com
Endometrial cancer is the most common gynaecological cancer in high income countries
and its incidence is rising globally. Although an ageing population and fewer benign …

Current evidence-based systemic therapy for advanced and recurrent endometrial cancer

S Gordhandas, WA Zammarrelli, EV Rios-Doria… - Journal of the National …, 2023 - jnccn.org
Endometrial cancer (EC) is the most common gynecologic malignancy, with worldwide
increasing incidence and disease-associated mortality. Although most patients with EC are …

Optimal management for stage IVB endometrial cancer: a systematic review

VA Capozzi, E Scarpelli, A De Finis, I Rotondella… - Cancers, 2023 - mdpi.com
Simple Summary Stage IVB endometrial cancer, as defined in the 2009 edition of the FIGO
staging system, encompasses a diverse group of patients with a wide-ranging distribution of …

Recent advances in endometrial cancer prevention, early diagnosis and treatment

H Baker-Rand, SJ Kitson - Cancers, 2024 - mdpi.com
Simple Summary Endometrial cancer is the fourth most common female malignancy in high
socioeconomic index nations and the sixth most common cancer in women worldwide. The …

Population-level uptake of neoadjuvant chemotherapy for stage IVB endometrial cancer

ND Jooya, MA Ciccone, LL Brunette, HQ Pham… - Gynecologic …, 2022 - Elsevier
Objective To examine population-level trends, characteristics, and outcomes of patients with
stage IVB endometrial cancer who received neoadjuvant chemotherapy (NACT) prior to …

Deciphering comprehensive features of tumor microenvironment controlled by chromatin regulators to predict prognosis and guide therapies in uterine corpus …

Q Wu, R Tian, J Liu, C Ou, Y Li, X Fu - Frontiers in Immunology, 2023 - frontiersin.org
Background Dysregulation of chromatin regulators (CRs) can perturb the tumor immune
microenvironment, but the underlying mechanism remains unclear. We focused on uterine …

Malignant mixed mullerian tumors: a SEER database review of rurality and treatment modalities on disease outcome

N Zadeh, A Bhatt, V Sripiparu, M Pasli… - Frontiers in …, 2024 - frontiersin.org
Introduction Malignant Mixed Mullerian Tumors (MMMT) are rare and poorly understood
sarcomas with limited research on risk factors, pathogenesis, and optimal treatments. This …

Sociodemographic, clinical characteristics, and treatment patterns of endometrial cancer cases in Puerto Rico during the period 2009 to 2015: A retrospective study

Y Pagán Santana, M Castañeda Ávila, R Ríos Motta… - Plos one, 2024 - journals.plos.org
Background Over the past decades, the rising incidence rates of endometrial cancer have
made it a significant public health concern for women worldwide. Treatment strategies for …

[HTML][HTML] Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas

A Jamieson, MK McConechy, A Lum, J Senz… - Journal of Gynecologic …, 2024 - ejgo.org
Objective Biomarkers reflecting real-time response to therapy and recurrence are lacking.
We assessed the clinical value of detecting cell-free circulating tumor DNA (ctDNA) …

Less is more in endometrial cancer (SLN, conservative treatment, radical hysterectomy, molecular classification)

G Parpex, C Lieng, M Koskas - Current Opinion in Oncology, 2022 - journals.lww.com
The predictive value and the safety of sentinel lymph node biopsy explain why most
societies propose to abandon systematic pelvic and para aortic lymphadenectomy. For …